David E. Kandzari, MD

Calcium Corner

Three-Year Data From BIOFLOW V: The Orsiro vs the Xience Drug-Eluting Stents

05/11/2020

The 3-year data have shown us a continued, highly significant statistically but also very clinically meaningful difference in the outcomes of target vessel-related myocardial infarction, target lesion revascularization, and the composite of...

The 3-year data have shown us a...

05/11/2020

Cath Lab Digest

Original Contribution

Clinical Outcomes with Drug-Eluting Stents following Atheroablation Therapies

08/01/2008

David E. Kandzari , MD;

Sunil V. Rao , MD, FACC, FSCAI;

Emily Honeycutt , MD;

Treatment with drug-eluting stents (DES) has revolutionized percutaneous coronary intervention (PCI) due to their substantial efficacy in reducing restenosis and the need for repeat revascularization procedures. Despite this benefit, the...

Treatment with drug-eluting...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

The Impact of Age and Sex on In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention

01/15/2017

James W. Choi , MD;

Ehtisham Mahmud , MD;

Mitul P. Patel , MD;

Khaldoon Alaswad , MD;

Jeffrey W. Moses , MD;

Dimitrios Karmpaliotis , MD, PhD;

Ziad A. Ali , MD, DPhil;

Farouc A. Jaffer , MD, PhD;

Manish A. Parikh , MD;

Robert W. Yeh , MD, MBA, MSc;

Aris Karatasakis , MD;

Michael R. Wyman , MD;

Barbara Anna Danek , MD;

J. Aaron Grantham , MD;

Judit Karacsonyi , MD, PhD;

Nicholas J. Lembo , MD;

Bavana V. Rangan , BDS, MPH, MD;

Anthony H. Doing , MD;

Ajay J. Kirtane , MD, SM;

Emmanouil S. Brilakis , MD, PhD, FACC, FAHA, FESC, FSCAI;

Craig A. Thompson , MD, MMSc;

Barry F. Uretsky , MD;

Subhash Banerjee , MD, FSCAI;

Rahel Iwnetu , MD;

William L. Lombardi , MD;

David E. Kandzari , MD;

Catalin Toma , MD;

We sought to determine the effect of age and sex on procedural outcomes and efficiency of chronic total occlusion percutaneous coronary intervention.

We sought to determine the...

01/15/2017

Journal of Invasive Cardiology

Original Contribution

Temporal Trends in Target Vessel Revascularization in Clinical Practice: Long-Term Outcomes following Coronary Stenting
from th

08/01/2008

Robert H. Tuttle , MSPH;

James G. Jollis ;

David E. Kandzari , MD;

James P. Zidar , MD;

Randomized clinical trials evaluating coronary stents versus balloon angioplasty have demonstrated marked improvements in the short- and long-term safety and efficacy of percutaneous coronary intervention (PCI) by reducing restenosis and the...

Randomized clinical trials...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

The Impact of Proximal Vessel Tortuosity on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry

05/15/2017

Ziad A. Ali , MD, DPhil;

Manish A. Parikh , MD;

Aris Karatasakis , MD;

Dimitrios Karmpaliotis , MD, PhD;

Barbara Anna Danek , MD;

Farouc A. Jaffer , MD, PhD;

Judit Karacsonyi , MD, PhD;

Robert W. Yeh , MD, MBA, MSc;

Imre Ungi , MD, PhD;

Bavana V. Rangan , BDS, MPH, MD;

Michael R. Wyman , MD;

Ajay J. Kirtane , MD, SM;

Subhash Banerjee , MD, FSCAI;

Nicholas J. Lembo , MD;

Barry F. Uretsky , MD;

David E. Kandzari , MD;

Anthony H. Doing , MD;

William L. Lombardi , MD;

Craig A. Thompson , MD, MMSc;

Ehtisham Mahmud , MD;

Catalin Toma , MD;

Mitul P. Patel , MD;

James W. Choi , MD;

Santiago Garcia , MD;

Aya J. Alame , BA;

Khaldoon Alaswad , MD;

José Roberto Martínez-Parachini , MD;

Erica Resendes , BS, MS, MPH;

Emmanouil S. Brilakis , MD, PhD, FACC, FAHA, FESC, FSCAI;

Jeffrey W. Moses , MD;

We examined the impact of proximal vessel tortuosity on the outcomes of chronic total occlusion percutaneous coronary intervention.

We examined the impact of...

05/15/2017

Journal of Invasive Cardiology

Integrating GP IIb/IIIa Inhibition into Treatment Strategies for Acute ST-Elevation Myocardial Infarction (Part II)

08/01/2008

Matthew T. Roe , MD, MHS;

David E. Kandzari , MD;

“Facilitated fibrinolysis”: GP IIb/IIIa inhibitors and fibrinolytic therapy in ST-elevation infarction. Considering the abundant platelet-rich thrombus present in almost all patients with acute myocardial infarction, it is intuitive that...

“Facilitated fibrinolysis”: GP...

08/01/2008

Journal of Invasive Cardiology

Review

Anaphylactoid Reactions to Radiocontrast Agents: Prevention and Treatment in the Cardiac Catheterization Laboratory

10/09/2009

Keshav R. Nayak , MD;

Andrew A. White , MD;

Jeffrey J. Cavendish , MD;

Colin M. Barker , MD, FACC, FSCAI;

David E. Kandzari , MD;

ABSTRACT: The use of iodinated contrast agents for angiography dates back to the 1920s.1 The initial prototype has undergone modifications to reduce the toxicity and discomfort associated with the early contrast molecules. More importantly,...

ABSTRACT: The use of iodinated...

10/09/2009

Journal of Invasive Cardiology

Original Contribution

Use of Saphenous Vein Bypass Grafts for Retrograde Recanalization of Coronary Chronic Total Occlusions: Insights From a Multicenter Registry

05/27/2016

William L. Lombardi , MD;

Khaldoon Alaswad , MD;

Dimitrios Karmpaliotis , MD, PhD;

J. Aaron Grantham , MD;

Nicholas J. Lembo , MD;

Craig A. Thompson , MD, MMSc;

Colby R. Ayers , MS;

Phuong-Khanh J. Nguyen-Trong , MD;

Emmanouil S. Brilakis , MD, PhD, FACC, FAHA, FESC, FSCAI;

Subhash Banerjee , MD, FSCAI;

Aris Karatasakis , MD;

David E. Kandzari , MD;

Barbara Anna Danek , MD;

Judit Karacsonyi , MD, PhD;

Michele Roesle , RN, BSN, MD;

Bavana V. Rangan , BDS, MPH, MD;

The use of SVGs for retrograde native vessel CTO-PCI has received limited study. We reviewed the medical records and coronary angiograms of retrograde CTO-PCIs performed through an SVG at 4 U.S. institutions between 2012 and 2013.

The use of SVGs for retrograde...

05/27/2016

Journal of Invasive Cardiology

Integrating GP IIb/IIIa Inhibition into Treatment Strategies for Acute ST-Elevation Myocardial Infarction (PART I)

08/01/2008

David E. Kandzari , MD;

Matthew T. Roe , MD, MHS;

Overview. Against the background of established clinical benefit in non-ST segment elevation acute coronary syndromes (ACS) and elective percutaneous revascularization, recent trials examining the role of glycoprotein (GP) IIb/IIIa inhibition...

Overview. Against the background...

08/01/2008

Journal of Invasive Cardiology

Clinical Editor's Corner

What Should We Do With an Anomalous Coronary Artery (ALCA) With a Malignant Left Main Course in an Asymptomatic Patient?

05/07/2018

Morton J. Kern , MD, MSCAI, FACC, FAHA;

Michael J. Lim , MD;

John W. Hirshfeld Jr.;

Kirk N. Garratt , MD, MSc;

Christopher J. White , DO, MD;

George W. Vetrovec , MD;

Jeannie Yu , MD;

Andrew Doorey ;

Pinak Bipin Shah ;

Jeffrey W. Moses , MD;

Paul S. Teirstein , MD, FACC;

William M. Suh , MD;

David E. Kandzari , MD;

Dr. Paul Teirstein, Chief of Cardiology, at Scripps Clinic, La Jolla, California, asked our cath lab experts for their opinions on what to do with an asymptomatic executive who had a screening CTA (Figure 1).

Dr. Paul Teirstein, Chief of...

05/07/2018

Cath Lab Digest